A Phase 2 clinical trial of Harbour BioMed‘s investigational therapy batoclimab, also known as HBM9161, for myasthenia gravis (MG), has started dosing patients, the company said in a press release. The trial (NCT04346888) — being conducted at the Huashan Hospital in Shanghai, China — is…
For the first time, a real-world study comparing the effects of long-term intravenous (IVIG) and subcutaneous immunoglobulin (SCIG) maintenance therapy in adults with generalized myasthenia gravis (gMG) showed reduced impairments, less use of other medications, and improved…
A large-scale analysis of people with myasthenia gravis (MG) in North America revealed a higher prevalence of MG and other autoimmune disorders among their families, suggesting there may be a genetic component to the neuromuscular condition, a study reported. The…
Among people with myasthenia gravis (MG) and thymoma — a tumor of the thymus — being male and having more severe disease, advanced thymoma, or post-surgery complications predict poorer outcomes, a study from China suggests. In turn, anticholinesterase therapies taken early and before surgery to remove the thymus…
Altered levels of immune proteins associated with the complement system may be implicated in generalized myasthenia gravis (MG), a new study suggests. The study, “Changes in serum complements and their regulators in generalised myasthenia gravis,” was published in the European Journal of Neurology. The complement system…
Women with myasthenia gravis (MG) have a diminished quality of life compared with male patients, and are particularly affected by the number of additional diseases (comorbidities) they experience, a new study from China reports. They also have a less active lifestyle, which may reveal…
Older patients with myasthenia gravis (MG) who receive treatment with intravenous immunoglobulin (IVIG) may be at a higher risk of developing coronary spastic angina, known as CSA, according to a recent case report. In CSA, muscle spasms in the walls of the coronary arteries can block blood…
The inflammatory molecule interleukin-36 (IL-36) gamma is associated with the severity of myasthenia gravis (MG), and may participate in disease processes by activating certain immune cells, a recent study suggests. The study, “Increased serum IL-36γ levels are associated with disease severity in myasthenia gravis patients,”…
A patient with three different types of myasthenia gravis (MG)-associated antibodies was described in a recent case report. The report, “Anti-MuSK positive myasthenia gravis with anti-Lrp4 and anti-titin antibodies,” was published in Internal Medicine. MG is caused by the immune system attacking the…
Same But Different, a U.K. nonprofit that uses the arts to bring communities together, is holding a calendar photography competition to raise awareness for rare diseases. Under the theme “A Glimmer of Hope,” the competition is a means to “visually express the hope that exists for people affected by…
Get regular updates to your inbox.